General Catalyst Group Management, LLC holds a concentrated book of 14 stocks worth $188.5M as of Q2 2026 (disclosed Aug 17, 2026, a ~48-day 13F lag). This quarter they opened Parabilis Medicines, Inc. and trimmed Fractyl Health Inc. Their largest long position is Arrivent Biopharma Inc at 28% of the equity book.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
69% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as General Catalyst Group Management, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 16 / 14 | $90.0B |
| BlackRock, Inc. | 14 / 14 | $260.3B |
| VANGUARD CAPITAL MANAGEMENT LLC | 14 / 14 | $220.6B |
| STATE STREET CORP | 14 / 14 | $152.5B |
| MORGAN STANLEY | 14 / 14 | $62.2B |
| GOLDMAN SACHS GROUP INC | 14 / 14 | $26.5B |
| VANGUARD FIDUCIARY TRUST CO | 14 / 14 | $19.6B |
| UBS Group AG | 14 / 14 | $13.6B |
Ranked by how many of General Catalyst Group Management, LLC's top 14 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | ArriVent BioPharma, Inc. COM | $51.9M | 1.49M | 27.5% | —Held | |
| 2 | Parabilis Medicines, Inc. COM | $43.8M | 1.60M | 23.2% | ▲New New position | |
| 3 | Maplebear, Inc. COM | $33.7M | 710.7K | 17.9% | —Held | |
| 4 | Maze Therapeutics, Inc. COM | $30.9M | 1.04M | 16.4% | —Held | |
| 5 | Odyssey Therapeutics, Inc. COMMON STOCK | $15.2M | 810.3K | 8.0% | ▲New New position | |
| 6 | Eikon Therapeutics, Inc. COM | $4.0M | 305.2K | 2.1% | —Held | |
| 7 | Fractyl Health, Inc. COM | $3.9M | 4.88M | 2.1% | ▼~0% Reduced · −7 sh | |
| 8 | Ethos Technologies, Inc. CL A | $1.3M | 74.2K | 0.7% | —Held | |
| 9 | Coupang Inc. CL A | $950K | 54.7K | 0.5% | ▲+49% Added · +18K sh | |
| 10 | Amazon.com Inc. COM | $925K | 3.9K | 0.5% | ▲+50% Added · +1K sh | |
| 11 | Meta Platforms Inc. CL A | $744K | 1.3K | 0.4% | ▲+101% Added · +662 sh | |
| 12 | Doordash Inc. CL A | $526K | 2.9K | 0.3% | ▲New New position | |
| 13 | Carvana Co CL A | $426K | 6.5K | 0.2% | ▲New New position | |
| 14 | Figma, Inc. CLASS A COM STK | $269K | 14.8K | 0.1% | —Held |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1637946/holdings"
Use Arkolith to show General Catalyst Group Management, LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.